Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tifacogin in severe community-acquired pneumonia
ACTRN12607000460404Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Jul 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 3, randomised trial of tifacogin in community-acquired pneumonia (CAP) (3 arms), sponsored by Novartis. Primary endpoint: 28-day all-cause mortality. Started Jul 2004; status: recruiting.
02
Drugs
tifacogin
03
Conditions
community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on ACTRN12607000460404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000460404.